Patent application number | Description | Published |
20080249126 | 1,3-SUBSTITUTED CYCLOALKYL DERIVATIVES HAVING ACIDIC, MOSTLY HETEROCYCLIC GROUPS, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS - The invention relates to 1,3-substituted cycloalkyl derivatives having acidic, mostly heterocyclic groups and to their physiologically acceptable salts and physiologically functional derivatives. | 10-09-2008 |
20090264402 | NOVEL DIPHENYLAZETIDINONE SUBSTITUTED BY PIPERAZINE-1-SULFONIC ACID AND HAVING IMPROVED PHARMACOLOGICAL PROPERTIES - The invention therefore relates to the compound of the formula I | 10-22-2009 |
20090298871 | SULFONYL-PHENYL-2H-[1,2,4]OXADIAZOL-5-ONE DERIVATIVES , PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS - The invention relates to sulfonyl-phenyl-oxadiazolones and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta or PPARdelta and PPARgamma agonist activity. | 12-03-2009 |
20100035834 | NOVEL 1,4-BENZOTHIEPIN-1, 1-DIOXIDE DERIVATIVES WITH IMPROVED PROPERTIES METHOD FOR PRODUCING THE SAME, DRUGS CONTAINING SAID COMPOUNDS AND THE USE THEREOF - This invention relates to Novel 1,4-benzothiepin-1,1-dioxide derivatives with improved properties, method for producing the same, drugs containing said compounds and use thereof. | 02-11-2010 |
20100035961 | Novel 1,4-benzothiepine 1,1-dioxide derivatives substituted by benzyl radicals, method for their preparation, pharmaceuticals comprising these compounds, and the use thereof - This invention relates to Novel 1,4-benzothiepine 1,1-dioxide derivatives substituted by benzyl radicals, method for their preparation, pharmaceuticals comprising these compounds, and the use thereof. | 02-11-2010 |
20100035962 | NOVEL 1,4-BENZOTHIEPIN-1,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH CYCLOHEXYL GROUPS, METHOD FOR PRODUCING THE SAME, DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF - This Invention relates to Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with cyclohexyl groups, method for producing the same, drugs containing said compounds and use thereof. | 02-11-2010 |
20100062991 | NOVEL 1,4-BENZOTHIEPIN-1,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH FLUORINE, METHOD FOR PRODUCING THE SAME, DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF - This invention relates to Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with fluorine, method for producing the same, drugs containing said compounds and use thereof. | 03-11-2010 |
Patent application number | Description | Published |
20080207534 | 1,4-BENZOTHIAZEPINE 1,1-DIOXIDE DERIVATIVE, PROCESS FOR ITS PREPARATION, MEDICAMENTS COMPRISING THIS COMPOUND, AND USE THEREOF AS A HYPOLIPIDAEMIC - The invention relates to the compound of the formula (A) and also to its physiologically acceptable salts. The compound is suitable as, for example, a hypolipidemic. | 08-28-2008 |
20080207592 | Novel 1,4-benzothiazepine-1,1-dioxide derivative having improved properties, method for the production thereof, medicaments containing said compound, and use thereof - The invention relates to the compound of the formula (A) and also to its physiologically acceptable salts. The compound is suitable as, for example, a hypolipidemic. | 08-28-2008 |
20080274947 | Hydroxy-Substituted Diphenylazetidinones for the Treatment of Hyperlipidemia - The present invention comprises compounds and compositions for the treatment of metabolic disorders and more particularly, those insulin-related metabolic disorders of the blood such as hyperlipidemia, diabetes, insulin-resistance and the like comprising diphenylazetidinones compounds which have an additional hydroxy function in the 2″ position and their salts. The invention therefore relates to compounds of formula I: | 11-06-2008 |
20090012131 | 4-OXY-N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR THERAPEUTIC USE - The present invention comprises 4-Oxy-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, the derivatives thereof and salts thereof as well as processes for their preparation and methods for their use as pharmaceutical compositions. More specifically, the invention relates to 4-oxy-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides and to their physiologically acceptable salts and physiologically functional derivatives that exhibit peroxisome proliferator activator receptor (PPAR) PPARalpha, PPARdelta and PPARgamma agonist activity. The compounds themselves are defined by the structure of the formula I, | 01-08-2009 |
20090054494 | N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR THEIR THERAPEUTIC USE - The present invention comprises N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, their physiologically acceptable salts and functional derivatives that exhibit peroxisome proliferator activated receptor (PPAR) PPARdelta and PPARgamma agonist activity. The structure of the compounds of the invention are defined by Formula I below, | 02-26-2009 |
20130203651 | PHARMACEUTICAL COMPOSITION FOR TREATING A METABOLIC SYNDROME - The invention is directed to a pharmaceutical composition containing at least one FGF-21 (fibroblast growth factor 21) compound, at least one GLP-1R (glucagon-like peptide-1 receptor) agonist and optionally at least one anti-diabetic drug and/or at least one DPP-4 (dipeptidyl peptidase-4) inhibitor for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas. | 08-08-2013 |
20140073563 | FUSION PROTEINS FOR TREATING A METABOLIC SYNDROME - The invention is directed to a fusion protein comprising at least one FGF-21 (fibroblast growth factor-21) compound and at least one GLP-1R (glucagon-like peptide-1 receptor) agonist as well as to pharmaceutical compositions, medical uses and methods of treatment involving the fusion protein, particularly in the field of diabetes, dyslipidemia, obesity and/or adipositas. | 03-13-2014 |
20140142023 | Pharmaceutical Composition for Treating A Metabolic Syndrome - The invention is directed to a pharmaceutical composition comprising at least one FGF-21 (fibroblast growth factor 21) compound, at least one GLP-1R (glucagon-like peptide-1 receptor) agonist and optionally at least one anti-diabetic drug and/or at least one DPP-4 (dipeptidyl peptidase-4) inhibitor for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas. The invention is also directed to a pharmaceutical composition comprising at least one FGF-21 (fibroblast growth factor 21) compound, at least one DPP-4 (dipeptidyl peptidase-4) inhibitor and optionally GLP-1R (glucagon-like peptide-1 receptor) agonist and/or at least one at least one anti-diabetic drug for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas. | 05-22-2014 |